Safety, Pharmacokinetics, and Antiviral Activity of GS-6207 Administered Subcutaneously in HIV-1 Infected Adults

Safety, Pharmacokinetics, and Antiviral Activity of GS-6207 Administered Subcutaneously in HIV-1 Infected Adults

GS-US-200-4072 · Trial · Opened 11/14/2018

Major Inclusion/Exclusion Criteria

1. 1. Never have taken HIV medications or have been off HIV medications more than 12 weeks
   2. No history of taking integrase inhibitor HIV medication
   3. Absolute CD4 > 200
   4. Willing to start Biktarvy on day 10 of the clinical trial
   5. No medications taken within 42 days prior to start of the study drug without prior approval from Sponsor

FULL DESCRIPTION HERE

Read more